Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma

Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma

Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is a monoclonal antibody that binds to IL-5 receptor alpha subunit and depletes peripheral blood eosinophils rap...

Full description

Bibliographic Details
Main Authors: José A. Cañas, Marcela Valverde-Monge, José M. Rodrigo-Muñoz, Beatriz Sastre, Marta Gil-Martínez, Raquel García-Latorre, Manuel J. Rial, Aida Gómez-Cardeñosa, Mar Fernández-Nieto, Erwin J. Pinillos-Robles, María J. Rodríguez-Nieto, Nicolás González-Mangado, Joaquín Sastre, Victoria del Pozo
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Journal of Personalized Medicine
Subjects:
benralizumab
biologic treatment
microRNA
severe eosinophilic asthma
Online Access:https://www.mdpi.com/2075-4426/11/2/76

Internet

https://www.mdpi.com/2075-4426/11/2/76

Similar Items